Literature DB >> 8771294

Prognosis of infections in elderly patients with haematological diseases.

F Rossini1.   

Abstract

The goal of work was to evaluate epidemiological features and prognostic factors of infections in elderly patients affected by haematological neoplasms. From 1 May 1989 to 30 April 1994 we observed 765 infectious episodes in 416 patients: 554 in patients younger than 65, 211 in patients aged over 65. No difference in rate of combined- or single-agent antibiotic therapy was present, nor in the rate of patients receiving growth factors. The outcome has been classified as positive, death from infections or death from causes other than infection (NID). When all deaths are considered, younger patients had a lower rate of death (120/554, 22%) than the elderly (59/211, 28%) P = 0.069 (Fisher's exact test). When NID are excluded 77/511 (15%) younger patients and 34/186 (18%) elderly patients died P = 0.34. A significantly higher rate of younger patients had an absolute neutrophil count (ANC) lower than 500/mm3 at the onset: younger patients 322/554 (58%), the elderly 79/211 (38%) P < 0.00001. When only neutropenic (ANC < 500/mm3) patients are considered, the difference in outcome between the two groups is more evident: positive outcome was achieved by 251/322 younger (78%) and by 49/79 elderly patients (62%) P = 0.004; when NID were excluded, positive outcome was achieved by 251/306 younger (82%) and by 49/68 elderly patients (72%) P = 0.066. Taking into account a higher rate of NID, it is possible to achieve an outcome for infection in the elderly that is not significantly different from that in younger patients, when less severe neutropenia is induced. However, among neutropenic patients, the prognosis for infections become poorer in elderly patients. This must be evaluated when aggressive chemotherapy for these patients is being designed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8771294     DOI: 10.1007/bf01769875

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  14 in total

Review 1.  Acute myeloid leukaemia in the elderly: biology and treatment.

Authors:  P R Johnson; J A Liu Yin
Journal:  Br J Haematol       Date:  1993-01       Impact factor: 6.998

2.  Hematopoiesis in the aged: a model of hematopoietic dysregulation?

Authors:  G Rothstein
Journal:  Blood       Date:  1993-11-01       Impact factor: 22.113

3.  Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study.

Authors:  J Yates; O Glidewell; P Wiernik; M R Cooper; D Steinberg; H Dosik; R Levy; C Hoagland; P Henry; A Gottlieb; C Cornell; J Berenberg; J L Hutchison; P Raich; N Nissen; R R Ellison; R Frelick; G W James; G Falkson; R T Silver; F Haurani; M Green; E Henderson; L Leone; J F Holland
Journal:  Blood       Date:  1982-08       Impact factor: 22.113

4.  Causes of initial remission induction failure in acute myelogenous leukemia.

Authors:  E H Estey; M J Keating; K B McCredie; G P Bodey; E J Freireich
Journal:  Blood       Date:  1982-08       Impact factor: 22.113

5.  Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients.

Authors:  J Klastersky; M P Glauser; S C Schimpff; S H Zinner; H Gaya
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

6.  Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.

Authors:  H Tilly; S Castaigne; D Bordessoule; P Casassus; P Y Le Prisé; G Tertian; B Desablens; M Henry-Amar; L Degos
Journal:  J Clin Oncol       Date:  1990-02       Impact factor: 44.544

Review 7.  Acute myelogenous leukemia: recent advances in therapy.

Authors:  R Champlin; R P Gale
Journal:  Blood       Date:  1987-06       Impact factor: 22.113

8.  Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.

Authors: 
Journal:  Ann Intern Med       Date:  1993-10-01       Impact factor: 25.391

9.  Amikacin and ceftazidime as empirical antibiotic therapy in severely neutropenic patients: analysis of prognostic factors.

Authors:  F Rossini; P Pioltelli; S Mingozzi; R Bregani; F Viganó; S Bolis; I Casaroli; E Lanzi; E M Pogliani; G Corneo
Journal:  Support Care Cancer       Date:  1994-07       Impact factor: 3.603

10.  Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem.

Authors:  A G Freifeld; T Walsh; D Marshall; J Gress; S M Steinberg; J Hathorn; M Rubin; P Jarosinski; V Gill; R C Young
Journal:  J Clin Oncol       Date:  1995-01       Impact factor: 44.544

View more
  1 in total

1.  Comparative study of clinical characteristics of neutropenic and non-neutropenic adult cancer patients with bloodstream infections.

Authors:  E Velasco; R Byington; C A S Martins; M Schirmer; L M C Dias; V M S C Gonçalves
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-01       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.